Recruiting
Phase 2

Enasidenib

Sponsor:

Washington University School of Medicine

Code:

NCT06240754

Conditions

Clonal Cytopenia of Undetermined Significance

CCUS Clonal Cytopenia of Undetermined Significance

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Enasidenib

Study Details

Brief summary:

Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.

Conditions

Clonal Cytopenia of Undetermined Significance

CCUS Clonal Cytopenia of Undetermined Significance

Study ID

NCT06240754

Start date

Oct 10, 2024

Status verified date

Aug, 2026

Completion date

Jun 30, 2029

Anticipated

Primary completion date

May 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Unexplained cytopenia for at least 6 months. Cytopenia is defined as the presence of ≥1 blood count indexes below the following thresholds:

  • Hgb <10 g/dL
  • ANC <1.8 × 109/L
  • Platelets <100 × 109/L
  • IDH2 gene mutation (R140 or R172), performed locally, at a frequency ≥ 2%.
  • At least 18 years of age.
  • ECOG performance status 0-2
  • Adequate organ function as defined below:

  • AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
  • Serum total bilirubin < 1.5 x IULN (un upper limit of bilirubin 5 mg/dL is acceptable if it can be attributed to Gilbert's syndrome or erythropoiesis)
  • Creatinine clearance > 50 mL/min by Cockcroft-Gault glomerular filtration rate estimation or serum creatinine ≤ 2 x IULN
  • The effects of enasidenib on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 24 months after the last dose of enasidenib. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and for 4 months after the last dose of enasidenib.
  • Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion Criteria:

  • Indication of hematologic disease by bone marrow biopsy within 6 months of study entry.

  • Evidence of disease progression from time of bone marrow biopsy to enrollment based on investigator review of symptoms and complete blood counts
  • Active malignancy (defined as > 1 cm disease on most recent CT scan in the past 6 months).
  • Currently receiving therapy for solid tumor malignancy or received within the last 6 months.
  • Currently receiving any other investigational agents.
  • Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to enasidenib or other agents used in the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 72 hours of study entry.
  • Positive direct Coombs test.

Study Design

Enrollment

15 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Enasidenib

Participants will receive enasidenib 100 mg daily for 18 cycles (each cycle is 28 days).

Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.

Interventions

Enasidenib

Provided by BMS.

Primary outcome measure

  • Best hematologic response [ Time Frame: Up to 18 cycles (each cycle is 28 days) of treatment (up to approximately 17 months) ]

Central Contacts and Locations

Central contacts

Giulia Petrone, M.D.

314-362-6826gpetrone@wustl.edu

Locations

Washington University School of Medicine

Recruiting

St Louis, Missouri, United States, 63110

Contacts

Giulia Petrone, M.D.

314-362-6826gpetrone@wustl.edu

Principal Investigator:

Giulia Petrone, M.D.

More Information

Sponsor

Washington University School of Medicine

Last update posted

Aug 10, 2026

Last verified

Aug, 2026

Keywords

  • Clonal Cytopenia of Undetermined Significance
  • CCUS
  • IDH2
  • Enasidenib

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2026-08-10.